Anticholinesterases in the treatment of Alzheimer's disease;Anticolinesterásicos en el tratamiento de la enfermedad de Alzheimer

Revista de Neurologia

Volumn 42, Issue 8, 2006, Pages 471-477

  Gandía Juan, Luis ^a,b   Alvarez R M ^a   Hernandez Guijo J M ^a   Gonzalez Rubio J M ^a   De Pascual, R ^a   Rojo, J ^a   Tapia, L ^a,b  

^a INSTITUTO TEÓFILO HERNANDO   (Spain)

^b AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

Alzheimer's disease; Anticholinesterases; Donepezil; Galanthamine; Neuroprotection; Rivastigmine

Indexed keywords

ACETYLCHOLINE; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ASCORBIC ACID; DONEPEZIL; GALANTAMINE; RIVASTIGMINE; SCOPOLAMINE; TACRINE; ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR;

ABDOMINAL PAIN; ALZHEIMER DISEASE; ANOREXIA; APOPTOSIS; BIOAVAILABILITY; CHOLINERGIC TRANSMISSION; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; HUMAN; HYDROLYSIS; NAUSEA; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; PATHOPHYSIOLOGY; REVIEW; UNSPECIFIED SIDE EFFECT; METABOLISM; PATHOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOPTOSIS; CHOLINESTERASE INHIBITORS; HUMANS; NEUROFIBRILLARY TANGLES; SYNAPTIC TRANSMISSION;

EID: 33750112315     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4208.2005227     Document Type: Review

References (52)

1. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215: 1237-9.
2. Selkoe DJ. Biochemistry of altered brain proteins in Alzheimer's disease. Annu Rev Neurosci 1989; 12: 463-90.
3. Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 1994; 17: 489-517.
4. Ávila J. Tau aggregation into fibrillar polymers: taupathies. FEBS Lett 2000; 476: 89-92.
5. Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-14.
6. García AG. Teoría colinérgica del Alzheimer. JANO 2000; 62: 1104.
7. Giacobini E. Cholinergic receptors in human brain: effects of aging and Alzheimer disease. J Neurosci Res 1990; 27: 548-60.
8. Schroder H, Giacobini E, Struble RG, Zilles K, Maelicke A. Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease. Neurobiol Aging 1991; 12: 259-62.
9. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 2000; 275: 5626-32.
10. Wang HY, Lee DH, Davis CB, Shank RP. Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J Neurochem 2000; 75: 1155-61.
11. Pettit DL, Shao Z, Yakel JL. Beta-amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci 2001; 21: RC112.
12. 2+ influx in PC12h cells in culture. Neurosci Lett 1994; 173: 147-50.
13. Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M, et al. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem 1998; 71: 2439-46.
14. Rattray M. Is there nicotinic modulation of nerve growth factor? Implications for cholinergic therapies in Alzheimer's disease. Biol Psychiatry 2001; 49: 185-93.
15. Kihara T, Shimohama S, Akaike A. Effects of nicotinic receptor agonists on beta-amyloid beta-sheet formation. Jpn J Pharmacol 1999; 79: 393-6.
16. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, et al. Alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J Biol Chem 2001; 276: 13541-6.
17. Kem WR. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res 2000; 113: 169-81.
18. Shimohama S, Kihara T. Nicotinic receptor-mediated protection against beta-amyloid neurotoxicity. Biol Psychiatry 2001; 49: 233-9.
19. Wolfe MS. Therapeutic strategies for Alzheimer's disease. Nat Rev Drug Discov 2002; 1: 859-66.
20. Fuentealba J, Gandía L. La sinapsis colinérgica. In García AG, ed. La huella nicotínica de la demencia. Madrid: Instituto Teófilo Hernando; 2006. p. 1-12.
21. Davis RE, Emmerling MR, Jaen JC, Moos WH, Spiegel K. Therapeutic intervention in dementia. Crit Rev Neurobiol 1993; 7: 41-83.
22. Amenta F, Parnetti L, Gallai V, Wallin A. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? Mech Ageing Dev 2001; 122: 2025-40.
23. Wurtman RJ, Blusztajn JK, Ulus IH, Coviella IL, Buyukuysal RL, Growdon JH, et al. Choline metabolism in cholinergic neurons: implications for the pathogenesis of neurodegenerative diseases. Adv Neurol 1990; 51: 117-25.
24. Drachman DA, Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974; 30: 113-21.
25. Levey AI. Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Proc Natl Acad Sci U S A 1996; 93: 13541-6.
26. Avery EE, Baker LD, Asthana S. Potential role of muscarinic agonists in Alzheimer's disease. Drugs Aging 1997; 11: 450-9.
27. Caine ED. Cholinomimetic treatment fails to improve memory disorders. N Engl J Med 1980; 303: 585-6.
28. Newhouse PA, Potter A, Corwin J, Lenox R. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology 1994; 10: 93-107.
29. Sahakian B, Jones G, Levy R, Gray J, Warburton D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 1989; 154: 797-800.
30. Standaert DG, Young AB. Tratamiento de los trastornos degenerativos del sistema nervioso central. In Goodman & Gilman. Las bases farmacológicas de la terapéutica. Vol. 1. Madrid: McGraw-Hill; 2001. p. 557-76.
31. Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr 2002; 14 (Suppl 1): 77-91.
32. Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res 2003; 28: 515-22.
33. Giacobini E. From molecular structure to Alzheimer therapy. Jpn J Pharmacol 1997; 74: 225-41.
34. Giacobini E. Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochem Int 1998; 32: 413-9.
35. Qizilbash N, Birks J, López-Arrieta J, Lewington S, Szeto S. Tacrine for Alzheimer's disease. Cochrane Library plus en español. Oxford: Update Software; 2004, no. 2.
36. Birks J, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer's disease. Cochrane Library plus en español. Oxford: Update Software; 2004, no. 2.
37. Birks J, Grimley-Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Library plus en español. Oxford: Update Software; 2004, no. 2.
38. Parys W. Development of Reminyl (galantamine), a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Alzheimers Rep 1998; 1 (Suppl): S19-20.
39. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321: 1445-9.
40. Olin J, Schneider L. Galantamine for Alzheimer's disease. The Cochrane Library, issue 2. Chichester, UK: John Wiley & Sons.
41. Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf 1998; 19: 465-80.
42. Lilienfeld S, Parys W. Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2000; 11 (Suppl 1): S19-27.
43. Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, Maelicke A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 1996; 49: 1-6.
44. Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque EX. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res 2000; 113: 199-206.
45. Albuquerque EX, Pereira EF, Bonfante-Cabarcas R, Marchioro M, Matsubayashi H, Alkondon M, et al. Nicotinic acetylcholine receptors on hippocampal neurons: cell compartment-specific expression and modulatory control of channel activity. Prog Brain Res 1996; 109: 111-24.
46. Santos MD, Alkondon M, Pereira EF, Aracava Y, Eisenberg HM, Maelicke A, et al. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 2002; 61: 1222-34.
47. 2+ signals and neurotransmitter release. Mol Pharmacol 2003; 64: 1217-26.
48. Zhang L, Zhou FM, Dani JA. Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol Pharmacol 2004; 66: 538-44.
49. Arias E, Alés E, Gabilán NH, Cano-Abad MF, Villarroya M, García AG, et al. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 2004; 46: 103-14.
50. Kihara T, Sawada H, Nakamizo T, Kanki R, Yamashita H, Maelicke A, et al. Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity. Biochem Biophys Res Commun 2004; 325: 976-82.
51. Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci U S A 2002; 99: 12432-7.
52. Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 2003; 306: 772-7.